Analyst OutlookAnalyst recommends an outperform rating with a target price of $72, indicating a strong positive outlook.
Clinical Trial ResultsDianthus released positive clinical data from its Phase II MaGic study investigating its active C1s inhibitor claseprubart for the treatment of generalized myasthenia gravis.
Dosing AdvantagesClaseprubart is competitive with other complement inhibitors approved in gMG, but with clear dosing advantages and potentially superior safety.
Safety ProfileThe safety profile looks clean with no infections, only one ANA positive conversion, and no autoimmune activation symptoms.